FMW Media's New to The Street TV announces the 357th episode
broadcasting of its nationally syndicated shows tonight, Wednesday,
June 22, 2022, at 11:00 PM PT on Fox Business Network.
New to The Street airs tonight its business
interviews with the following four (4) Companies:
1). Sun West Mortgage Company, Inc.'s interview
with Mr. Pavan Agarwal, CEO
2). Tonix Pharmaceuticals, Inc.'s (NASDAQ:
TNXP) interview with Dr. Seth Lederman, MD, and CEO.
3). PetVivo Holdings, Inc.'s (NASDAQ: PETV)
(NASDAQ: PETVW) interview with Mr. Mark Middleton, National Sales
Director.
4). Sekur Private Data, Ltd.'s (OTCQX:
SWISF) (CSE: SKUR) (FRA: GDT0) interview with Mr. Alain Ghiai,
CEO.
Airing tonight, Host Jane King welcomes Mr. Pavan
Agarwal, CEO at Sun West Mortgage Company, Inc. Sun West Mortgage
Company, for over 40 years, has offered mortgages for the low to
mid-income earners throughout the US and Caribbean. Pavan
passionately describes the quality of care that Sun West gives
every mortgage applicant. After years of development, The Company
rolled-out its Morgan™ platform, a technology-driven AI platform
that understands and appreciates the unique challenges of getting a
mortgage. As the first of its kind in the marketplace, the Morgan
platform is an empathetic technology that offers solutions that
intelligently adapt to a mortgage applicant's individual needs,
situations, and state of mind. Each loan officer and executive at
Sun West takes a human-to-human approach to each applicant,
ensuring everyone is fairly and kindly treated. The Morgan platform
takes artificial intelligence and creates a human-to-technology
interaction during the home buying process which eliminates stress,
anxiety, uncertainty, and risk, even for those with challenging
credit and employment history. Fair lending and fair equality are a
must at Sun West Mortgage. Pavan says you cannot have one without
the other, and his team, along with the Morgan platform, commit
themselves to each applicant with need-based compassion. You are
not just a number and a credit score; each applicant has unique
life issues, and Sun West Mortgage Company wants to understand each
applicant's needs. Pavan invites viewers to the "GAME ON," a live
and streamed event Saturday, June 25, 2022, in Las Vegas, Nevada.
Two successful sports icons from the football and baseball
professions, Hall of Famers Terrell "TO" Owens and Ivan "Pudge"
Rodriguez introduce the Morgan™ mortgage platform; they will show
how it works and provide tips and training to become a mine-set
campion. Everyone is welcome to the event; follow the link to
register: https://www.swmc.com/gameon/. The on-screen QR code is
available during the show; download or visit Sun West Mortgage
Company, Inc. - https://www.swmc.com/.
Tonight, CEO Dr. Seth Lederman, MD at Tonix
Pharmaceuticals, Inc. (NASDAQ: TNXP), is back in the studio at the
Nasdaq Marketplace speaking with New to The Street's TV Host Jane
King. Recently, TNXP released data during three oral presentations
at the 2022 American Transplant Congress held at the Center of
Transplantation Sciences, Massachusetts General Hospital. TNX-1500
sees exciting results as a therapy in eliminating transplant
rejections in the heart and kidneys. Through a collaboration with
Massachusetts General Hospital, part of the Harvard Medical School,
the TNX-1500 shows data for possible product development for
therapeutic prevention of organ transplant rejection. TNX-1500
shows exciting results to date. A particular molecule, CD40-ligand
(CD40L) appears to be the reason for transplant rejections. TNXP
engineered a monotherapy to block toxicities associated with CD40L;
its TNX-1500 in animal studies shows activities to prevent
rejections. Dr. Lederman talks about the monkeypox virus and
compares the West African and Central African variants. The West
African is the one the press reports about, with infections
worldwide not appearing deadly. The Central African variant, with
no reported cases, can be lethal. TNXP has two patented vaccines,
one for smallpox and the other for monkeypox. TNX-801 is a
horsepox-based live virus vaccine currently in development to
protect against monkeypox and smallpox. The monkeypox vaccine is
in-testing with lab monkeys; so far, results look promising in
possible prevention. The Company's fibromyalgia and Long-COVID
studies and clinical trials continue at TNXP. Exciting times for
the Company for their novel therapies and treatments; Dr. Lederman
will come back on a future show with further updates. The on-screen
QR code is available during the show; download or visit Tonix
Pharmaceuticals, Inc. - https://www.tonixpharma.com/.
Mr. Mark Middleton, National Sales Director at
PetVivo Holdings, Inc. (NASDAQ: PETV)
(NASDAQ: PETVW), and TV Host Jane King will talk on New to The
Street TV tonight about the Company and its products. PetVivo
Holdings, Inc. is a biomedical device company that manufactures,
commercializes, and licenses innovative medical devices and
therapeutics for companion animals. As PETV's National Sales
Director, Mark talks about his history within the pet products
industry, dealing with FDA manufacturing, product distributions,
capital markets, and mergers/acquisitions. He sees himself as a
perfect fit at PETV; he understands the veterinarians (DVMs) needs
for best practices and product result outcomes for their clients'
animals. The injectable patented Spryng with OsteoCushion
Technology treats osteoarthritis and joint afflictions while
providing rehabilitation treatments for horses and dogs and
continues to grow as a reliable DVM treatment. Being an
entirely naturally derived product, Spryng is superior to
competitors' non-biological, synthetic products, and the Spryng
treatment lasts longer. The PETV has a talent team who understands
science, finance, sales/marketing, manufacturing, distribution,
etc. With patience, persistence, and follow-through, Mark sees a
strong future for PETV. The on-screen QR code is available during
the show; download or visit PetVivo Holdings,
Inc. - https://petvivo.com/ and Spryng with
OsteoCushion Technology -
https://www.sprynghealth.com/.
Tonight, New to The Street TV airs the in-studio
interview at the Nasdaq Marketplace with Mr. Alain Ghiai, CEO
at Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0).
Talking with TV Anchor Jane King, Alain explains the workplace
dynamic that shifted to a hybrid work schedule where workers work
partially at home and office. While at home, employees log on to
corporate systems while using less secure home connections. Hackers
exploit these less secured home systems, creating a hacking portal
into corporate IT networks. Alain explains the Company's newest
encrypted product, "Chat-by-Invite." This new text message tool
gives subscribers an utterly private chat. It works when
the Sekur subscriber sends a text message to a recipient,
and a link appears that opens into a private, secure platform
hosted in Switzerland. Essentially, the chat occurs on the Swiss
servers owned and controlled by Sekur Private Data, Ltd. Once the
text message session completes, the text disappears. Hackers won't
know about the transmission because of the highly encrypted
military technology behind the product. There is no direct texting
on open-source platforms, making them invulnerable to cybersecurity
breaches. The SekurMail / SekurMessenger, SekurVoice,
SekurProVideo Conference, and other products are available now or
soon. Sekur's "Chat-by-Invite" app is available on iOS and Android;
go to Sekur.com to download it. Subscribers get
cybersecurity protections not available with open-source programs
for reasonable pricing. Domain migration for emails is available
for individuals and businesses. Alain invites viewers to the
tutorial videos on how the products work. The Company recently
uplifted its share onto the OTCQX trading platform at OTCMarkets,
and Alain explains the Company's goal in getting its share trading
on a US national stock exchange. The Company, with its recurring
revenues month over month from service subscribers, no debt, no
toxic finances, and money in the bank, the value proposition for
any investor looks attractive. As an added protection to
subscribers, Sekur Private Data, Ltd operates its internet
platforms and security businesses under the country of
Switzerland's very tough privacy laws. The on-screen QR code is
available during the show to download more info or visit Sekur
Private Data, Ltd. – http://www.Sekur.com.
About Sun West Mortgage Company,
Inc.:
Sun West Mortgage Company, Inc. dedicates itself
to offering its customers the best service. To accomplish this,
they empower their loan officers so that they can find great rates
and provide the most appropriate loan options for each customer –
at amazing speed. The Company focuses on technology, giving them an
edge in the mortgage industry to offer some of the fastest turn
times available – so the customer can get into the home of their
dreams sooner. They commit to their core values of people,
experience, technology, and product. Sun West's Morgan™ platform is
a technology and AI platform that understands and appreciates the
unique challenges of getting a mortgage. The platform is available
24 hours & 7 days a week. It was created to intuitively
understand simple and complex requests and gives end-users a
context-aware resolution of all daily requests, thereby resolving
challenges with rigorous efficiency. The Morgan platform provides
any inquiry, assistance, or service that an end-user require is
completed intuitively, in minutes, and without friction. Founded in
1980, Sun West services a multi-billion-dollar loan portfolio with
the perspective of "customers first" and the desire to make the
mortgage process easy and stress-free for prospective homeowners.
Licensed in 48 states, the District of Columbia, Puerto Rico, and
the US Virgin Islands, Sun West Mortgage Company, Inc. acts as the
lender and offers to finance qualified borrowers -
https://www.swmc.com/ & https://www.hellomorgan.com/.
On June 25, 2022, the "GAME ON" – Mortgage Hall of Fame
- Morgan™ event is available for everyone; the
link is
https://www.swmc.com/gameon/.
About Tonix Pharmaceuticals Holding Corp.
(NASDAQ: TNXP):
Tonix Pharmaceuticals Holding Corp. (NASDAQ:
TNXP) is a clinical-stage biopharmaceutical company focused on
discovering, licensing, acquiring, and developing small molecules
and biologics to treat and prevent human disease and alleviate
suffering. Tonix's portfolio comprises immunology, rare disease,
infectious disease, and central nervous system (CNS) product
candidates. Tonix's immunology portfolio includes biologics to
address organ transplant rejection, autoimmunity, and cancer.
TNX-15001 is a humanized monoclonal antibody targeting CD40-ligand
in development to prevent allograft and xenograft rejection and for
the treatment of autoimmune diseases. A Phase 1 study of TNX-1500
is expected to be initiated in the second half of 2022. Tonix's
rare disease portfolio includes TNX-29002 for the treatment of
Prader-Willi syndrome. The FDA has granted TNX-2900 Orphan-Drug
Designation. Tonix's infectious disease pipeline consists of a
vaccine in development to prevent smallpox and monkeypox called
TNX-8013, next-generation vaccines to prevent COVID-19, and an
antiviral to treat COVID-19. Tonix's lead vaccine candidates for
COVID-19 are TNX-1840 and TNX-18504, live virus vaccines based on
Tonix's recombinant pox vaccine (RPV) platform. TNX-35005
(sangivamycin, i.v. solution) is a small molecule
antiviral drug to treat acute COVID-19 and is in the pre-IND stage
of development. TNX-102 SL, (cyclobenzaprine HCl sublingual
tablets) is a small molecule drug being developed to treat Long
COVID, a chronic post-acute COVID-19 condition. Tonix expects to
initiate a Phase 2 study in Long COVID in the second quarter of
2022. The Company's CNS portfolio includes small molecules and
biologics to treat pain, neurologic, psychiatric and addiction
conditions. Tonix's lead CNS candidate, TNX-102 SL, is in mid-Phase
3 development to manage fibromyalgia, with a new Phase 3 study
launched in the second quarter of 2022. Finally, TNX-13006 is a
biologic designed to treat cocaine intoxication that is expected to
start a Phase 2 trial in the second quarter of 2022
- https://www.tonixpharma.com. (1TNX-1500 is an
investigational new biologic at the pre-IND stage of development
and has not been approved for any indication.2TNX-2900 is an
investigational new drug at the pre-IND stage of development and
has not been approved for any indication. 3TNX-801 is a live
horsepox virus vaccine for percutaneous administration in
development to protect against smallpox and monkeypox. TNX-801 is
an investigational new biologic and has not been approved for any
indication.4TNX-1840 and TNX-1850 are live horsepox virus vaccines
for percutaneous administration, in development to protect against
COVID-19. TNX-1840 and TNX-1850 are designed to express the
SARS-CoV-2 spike protein from the omicron and BA.2 variants,
respectively. TNX-1840 and TNX-1850 are investigational new
biologics at the pre-IND stage of development and have not been
approved for any indication. 5TNX-3500 is an investigational new
drug at the pre-IND stage of development and has not been approved
for any indication. 6TNX-1300 is an investigational new biologic
and has not been approved for any indication.)
About PetVivo Holdings, Inc. (NASDAQ:
PETV) (NASDAQ: PETVW):
PetVivo Holdings, Inc. (NASDAQ: PETV)
(NASDAQ: PETVW) is an emerging biomedical device company currently
focused on manufacturing, commercializing, and licensing innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies to treat
companion animals time-efficiently and less costly. A key component
of this strategy is the accelerated timeline to revenues for
veterinary medical devices that enter the market much earlier than
more stringently regulated pharmaceuticals and biologics. PetVivo
has a pipeline of seventeen products to treat animals and people. A
portfolio of nineteen patents protects the Company's biomaterials,
products, production processes, and use methods. The Company's lead
product Spryng with OsteoCushion Technology, a
veterinarian-administered, intraarticular injection to treat
lameness and other joint-related affliction, including
osteoarthritis, in dogs and horses, is currently available for
commercial sale to veterinarians
- https://petvivo.com/ & https://www.sprynghealth.com/.
About Sekur Private Data Ltd. (OTCQX:
SWISF) (CSE: SKUR) (FRA: GDT0):
Sekur Private Data, Ltd. (fka- GlobeX Data,
Ltd.) (OTCQX: SWISF) (CSE: SKUR) (FRA:
GDT0) is a Cybersecurity and Internet privacy
provider of Swiss hosted solutions for secure communications and
secure data management. The Company distributes encrypted emails,
secure messengers, secure communication tools, secure cloud-based
storage, disaster recovery, and document management products. The
Company sells and serves consumers, businesses, and governments
worldwide through approved wholesalers, distributors, and
telecommunications companies. Contact Sekur Private Data, Ltd. at
corporate@globexdatagroup.com or
visit https://www.sekurprivatedata.com and https://www.sekur.com.
About FMW Media:
FMW Media operates one of the longest-running US
and International sponsored and Syndicated Nielsen Rated
programming TV brands, "New to The Street" and its blockchain show
"Exploring The Block." Since 2009, these brands have run
biographical interview segment shows across major U.S. Television
networks. The paid-for-TV programming platforms can potentially
reach over 540 million homes in the US and international markets.
FMW's New to The Street / Newsmax TV broadcasting platform airs its
syndication on Sundays at 10 -11 AM ET. FMW is also one of the
nation's largest buyers of linear television, long and short-form
paid programming
- https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/.
Forward-Looking Statements
Disclaimer:
This press release contains forward-looking
statements within Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934. In
some cases, you can identify forward-looking statements by the
following words: "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "ongoing," "plan,"
"potential," "predict," "project," "should," "will," "would," or
the negative of these terms or other comparable terminology.
However, not all forward-looking statements contain these words.
Forward-looking statements are not a guarantee of future
performance or results and will not necessarily be accurate
indications of the times at which such performance or results are
achieved. This press release should be considered in all filings of
the Companies contained in the Edgar Archives of the Securities and
Exchange Commission at www.sec.gov.
CONTACT:
FMW Media Contact:
Bryan Johnson +1 (631) 766-7462
Bryan@NewToTheStreet.com
"New to The Street" Business Development Office
1-516-696-5900 Support@NewtoTheStreet.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/fa1c1a5a-4cee-4aa4-969b-adf47961e915
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Aug 2024 to Sep 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Sep 2023 to Sep 2024